Atlas Trials

Safety and Immunogenicity of Recombinant COVID-19 Vaccine (Sf9 Cell) as a Booster

Clinical trial NCT05463354 · COMPLETED

Trial details

NCT number
NCT05463354
Sponsor
WestVac Biopharma Co., Ltd.
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
COVID-19SARS-CoV-2 Infection
Start date
2022-07-11
Primary completion
2022-08-18
Enrollment
410

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.